ERBB2 and triple-negative breast carcinoma: Patients with specific subtypes, namely hormone receptor (HR)−/human epidermal growth factor receptor 2 (HER2)+ and triple-negative breast cancer (TNBC), can achieve pCR rates of up to 68%3–5.